SEC Form 4 · accession 0001250853-19-000046
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 7:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.91 | Feb 1, 2019 | A | 400,000 | A | — | Jan 31, 2029 | Common Stock | 400,000 | 400,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 1, 2019 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option will vest as to 25% after one year following the date of grant, and the remainder will vest in 36 equal monthly installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Common Stock.
- F3The restricted stock units shall vest in four equal annual installments following the date of grant.